Association of HSP70-hom genetic variant with prostate cancer risk

Sana Sfar, Hamadi Saad, Faouzi Mosbah, Lotfi Chouchane

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Because of the importance of androgens to prostate cancer (PCa) development, several candidate genes along androgen pathway have been under intensive study. Given the role of the molecular chaperone HSP70 in the regulation of the androgen receptor (AR) transactivation function, we first chose to explore the association between the HSP70-hom functional genetic variant (+2437 T > C) and prostate cancer risk by genotyping DNA samples from 101 unselected PCa patients and 105 healthy men. There was a trend towards lower frequency of TC and CC genotypes among patients when compared with healthy controls, however the difference did not reach the statistical significance (TC genotype: OR = 0.53, P = 0.05; CC genotype: OR = 0.42, P = 0.16). Moreover, individuals carrying at least one C allele have a statistically significant lower susceptibility for PCa (OR = 0.51 (0.26-0.97); P = 0.02). Since some factors may influence tumor progression rather than initiation, we also examined the relationship between the HSP70-hom polymorphism and the clinical characteristics of the malignancy at the time of diagnosis. The stratified analysis of the genotypes with the clinical stage and tumor grade showed that there was no significant difference in the risk estimates according to prognostic indicators of PCa disease in our population study. This is the first report on the studies of HSP70 SNPs in PCa and our data suggest that this genetic variant may be a genetic marker for PCa susceptibility in Tunisians.

Original languageEnglish
Pages (from-to)459-464
Number of pages6
JournalMolecular Biology Reports
Volume35
Issue number3
DOIs
Publication statusPublished - Sep 2008
Externally publishedYes

Fingerprint

Androgens
Tumors
Prostatic Neoplasms
Molecular Chaperones
Androgen Receptors
Polymorphism
Genotype
Genes
DNA
Neoplasms
Genetic Markers
Transcriptional Activation
Single Nucleotide Polymorphism
Alleles
Population

Keywords

  • Clinical outcome
  • Genetic polymorphism
  • Genetic susceptibility
  • HSP70-hom
  • Prostate cancer

ASJC Scopus subject areas

  • Genetics
  • Cell Biology
  • Biochemistry

Cite this

Association of HSP70-hom genetic variant with prostate cancer risk. / Sfar, Sana; Saad, Hamadi; Mosbah, Faouzi; Chouchane, Lotfi.

In: Molecular Biology Reports, Vol. 35, No. 3, 09.2008, p. 459-464.

Research output: Contribution to journalArticle

Sfar, Sana ; Saad, Hamadi ; Mosbah, Faouzi ; Chouchane, Lotfi. / Association of HSP70-hom genetic variant with prostate cancer risk. In: Molecular Biology Reports. 2008 ; Vol. 35, No. 3. pp. 459-464.
@article{de02848858904692bb3770f961a5763b,
title = "Association of HSP70-hom genetic variant with prostate cancer risk",
abstract = "Because of the importance of androgens to prostate cancer (PCa) development, several candidate genes along androgen pathway have been under intensive study. Given the role of the molecular chaperone HSP70 in the regulation of the androgen receptor (AR) transactivation function, we first chose to explore the association between the HSP70-hom functional genetic variant (+2437 T > C) and prostate cancer risk by genotyping DNA samples from 101 unselected PCa patients and 105 healthy men. There was a trend towards lower frequency of TC and CC genotypes among patients when compared with healthy controls, however the difference did not reach the statistical significance (TC genotype: OR = 0.53, P = 0.05; CC genotype: OR = 0.42, P = 0.16). Moreover, individuals carrying at least one C allele have a statistically significant lower susceptibility for PCa (OR = 0.51 (0.26-0.97); P = 0.02). Since some factors may influence tumor progression rather than initiation, we also examined the relationship between the HSP70-hom polymorphism and the clinical characteristics of the malignancy at the time of diagnosis. The stratified analysis of the genotypes with the clinical stage and tumor grade showed that there was no significant difference in the risk estimates according to prognostic indicators of PCa disease in our population study. This is the first report on the studies of HSP70 SNPs in PCa and our data suggest that this genetic variant may be a genetic marker for PCa susceptibility in Tunisians.",
keywords = "Clinical outcome, Genetic polymorphism, Genetic susceptibility, HSP70-hom, Prostate cancer",
author = "Sana Sfar and Hamadi Saad and Faouzi Mosbah and Lotfi Chouchane",
year = "2008",
month = "9",
doi = "10.1007/s11033-007-9107-1",
language = "English",
volume = "35",
pages = "459--464",
journal = "Molecular Biology Reports",
issn = "0301-4851",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Association of HSP70-hom genetic variant with prostate cancer risk

AU - Sfar, Sana

AU - Saad, Hamadi

AU - Mosbah, Faouzi

AU - Chouchane, Lotfi

PY - 2008/9

Y1 - 2008/9

N2 - Because of the importance of androgens to prostate cancer (PCa) development, several candidate genes along androgen pathway have been under intensive study. Given the role of the molecular chaperone HSP70 in the regulation of the androgen receptor (AR) transactivation function, we first chose to explore the association between the HSP70-hom functional genetic variant (+2437 T > C) and prostate cancer risk by genotyping DNA samples from 101 unselected PCa patients and 105 healthy men. There was a trend towards lower frequency of TC and CC genotypes among patients when compared with healthy controls, however the difference did not reach the statistical significance (TC genotype: OR = 0.53, P = 0.05; CC genotype: OR = 0.42, P = 0.16). Moreover, individuals carrying at least one C allele have a statistically significant lower susceptibility for PCa (OR = 0.51 (0.26-0.97); P = 0.02). Since some factors may influence tumor progression rather than initiation, we also examined the relationship between the HSP70-hom polymorphism and the clinical characteristics of the malignancy at the time of diagnosis. The stratified analysis of the genotypes with the clinical stage and tumor grade showed that there was no significant difference in the risk estimates according to prognostic indicators of PCa disease in our population study. This is the first report on the studies of HSP70 SNPs in PCa and our data suggest that this genetic variant may be a genetic marker for PCa susceptibility in Tunisians.

AB - Because of the importance of androgens to prostate cancer (PCa) development, several candidate genes along androgen pathway have been under intensive study. Given the role of the molecular chaperone HSP70 in the regulation of the androgen receptor (AR) transactivation function, we first chose to explore the association between the HSP70-hom functional genetic variant (+2437 T > C) and prostate cancer risk by genotyping DNA samples from 101 unselected PCa patients and 105 healthy men. There was a trend towards lower frequency of TC and CC genotypes among patients when compared with healthy controls, however the difference did not reach the statistical significance (TC genotype: OR = 0.53, P = 0.05; CC genotype: OR = 0.42, P = 0.16). Moreover, individuals carrying at least one C allele have a statistically significant lower susceptibility for PCa (OR = 0.51 (0.26-0.97); P = 0.02). Since some factors may influence tumor progression rather than initiation, we also examined the relationship between the HSP70-hom polymorphism and the clinical characteristics of the malignancy at the time of diagnosis. The stratified analysis of the genotypes with the clinical stage and tumor grade showed that there was no significant difference in the risk estimates according to prognostic indicators of PCa disease in our population study. This is the first report on the studies of HSP70 SNPs in PCa and our data suggest that this genetic variant may be a genetic marker for PCa susceptibility in Tunisians.

KW - Clinical outcome

KW - Genetic polymorphism

KW - Genetic susceptibility

KW - HSP70-hom

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=48249126844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249126844&partnerID=8YFLogxK

U2 - 10.1007/s11033-007-9107-1

DO - 10.1007/s11033-007-9107-1

M3 - Article

C2 - 17578680

AN - SCOPUS:48249126844

VL - 35

SP - 459

EP - 464

JO - Molecular Biology Reports

JF - Molecular Biology Reports

SN - 0301-4851

IS - 3

ER -